Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed to Conduct Personalized Cancer Dx Trials with Georgetown

NEW YORK (GenomeWeb News) – Germany's Indivumed said today that it will conduct clinical research on personalized medicines for cancer in partnership with Georgetown University.

The trials will be conducted at the recently founded Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown.

Since 2007, Hamburg-based Indivumed and Georgetown have collaborated to establish a biobank and clinical database for analyzing tumor specimens to improve cancer diagnostics and to better understand the complex interaction of the cells within a tumor, Indivumed said.

"We will for the first time use our knowledge to treat cancer patients under the conditions of a clinical trial," Hartmut Juhl, CEO and founder of Indivumed, said in a statement.

"First, during surgery or prior to drug therapy, we sample and process tumor tissue under highly standardized conditions," Juhl said. "Following a thorough analysis of the tissue and after considering the tumor characteristics and the clinical history of the patients, we then recommend a targeted therapy for the individual patient."

Indivumed said that it expects the research to result in new diagnostic standards for cancer patients, and that it will initially focus on gastrointestinal cancers such as esophageal, colorectal, gastric, pancreatic, and liver cancers.

The Ruesch Center for the Cure of Gastrointestinal Cancers was founded at Georgetown last month and is named after the late businessman and philanthropist Otto Ruesch, who died of pancreatic cancer in 2004. His widow Jeanne Ruesch endowed a $ 6.75 million gift to create the center.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.